BioMedNewsBreaks

TuesdayAug 09, 2022 12:37 pm

BioMedNewsBreaks – InMed Pharmaceuticals Inc. (NASDAQ: INM) Announces Board Appointment, Changes

InMed Pharmaceuticals (NASDAQ: INM), a leader in the research, development, manufacturing and commercialization of rare cannabinoids, today announced the appointment of Nicole Lemerond to its board of directors, effective immediately. Lemerond is a financial executive with over 25 years of experience in investment management, private equity, investment banking and leveraged finance. Throughout her career, she has established and led health care groups at leading investment firms and has also worked at several large financial institutions, including Lehman Brothers and The Carlyle Group. Concurrent with Lemerond’s appointment, Adam Cutler has decided to transition off the board of directors. Cutler has served…

Continue Reading

TuesdayAug 09, 2022 11:58 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) Unveils Equity Program, Releases Q1 Financial Report

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), has announced an at-the-market equity program allowing the company to issue and sell up to $35 million of common shares. According to the announcement, the shares can be sold “from time to time” through the Neo Exchange, the NYSE American LLC or any other “marketplace” upon which the shares are listed, quoted or traded, at the prevailing market price at the time of sale. The company anticipates using any proceeds from the sales of these shares for growth opportunities and working capital initiatives. In addition, Cybin…

Continue Reading

ThursdayAug 04, 2022 1:16 pm

BioMedNewsBreaks – Silo Pharma Inc. (SILO) Reports Positive Results from Research on Novel Liposomes

Silo Pharma (OTCQB: SILO) recently announced it had produced an initial batch of SPU-21 liposomes for a rheumatoid arthritis study conducted by Frontage Laboratories, a contract research organization (“CRO”). “Recent research by the company revealed that SPU-21 liposomes have the ability to target inflamed epithelium, suggesting they can be used to target drug delivery. Further, SPU-21 can potentially be used to develop fusion imaging molecules and/or nanoparticles to study arthritic pathogenesis. According to the research, this approach may enhance therapeutic effects and decrease potential toxicity despite systemic administration of the drug,” a recent article reads. “In addition, Silo recently announced…

Continue Reading

ThursdayAug 04, 2022 12:07 pm

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Unveils New Corporate Website

Odyssey Health (OTC: ODYY), a company focused on developing unique, life-saving medical products, today announced the launch of its new corporate website. Consistent with the company’s recent name change, the new website was designed to better reflect Odyssey Health’s mission and focus while also improving communication strategies with current and potential shareholders, institutions, and various scientific and financial publications. “The launch of our new website is an important next step in the ongoing evolution of Odyssey and will enable us to provide more transparent communications with our shareholders and other stakeholders,” said Odyssey Health CEO Michael Redmond. “We are excited…

Continue Reading

WednesdayAug 03, 2022 2:36 pm

BioMedNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Poised to Accelerate Its CYB004 Clinical Development Program

Cybin (NYSE American: CYBN) (NEO: CYBN), a leading ethical biopharmaceutical company working to advance psychedelic therapeutics for various psychiatric and neurological conditions, has completed the acquisition of a phase 1 N,N-Dimethyltryptamine (“N,N-DMT”) study, the largest DMT study to date. The study provides key data relating to the company’s proprietary CYB004 substance with the potential to effectively treat anxiety disorders. “The phase 1 EBRX-101 study, now named CYB004-E, was acquired from Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) FSE: 1XU1) through Cybin IRL Limited, Cybin’s wholly owned subsidiary… The adaptive, randomized, double-blinded, placebo-controlled, single-ascending-dose study produced notable results. According to the…

Continue Reading

TuesdayAug 02, 2022 12:20 pm

BioMedNewsBreaks – Aditxt Inc. (NASDAQ: ADTX) Featured in Bell2Bell Podcast

Aditxt (NASDAQ: ADTX) was featured in the Bell2Bell Podcast, a part of IBN’s (InvestorBrandNetwork) sustained effort to provide specialized content distribution via widespread syndication channels. Amro Albanna, co-founder, chairman and CEO of Aditxt, joined the latest episode to provide an overview of the company and discuss its business model. “We are a biotech innovation company, and our focus is on immune diseases. The reality is that immune diseases are caused either by someone having too little immune response or too much immune response,” Albanna said. “When you have too little immune response and you’re dealing with COVID-19, we all understand…

Continue Reading

ThursdayJul 28, 2022 1:05 pm

BioMedNewsBreaks – QSAM Biosciences Inc. (QSAM) Targeting Significant Unmet Medical Need with CycloSam(R)

QSAM Biosciences (OTCQB: QSAM) is a company developing a new class of drugs called radiopharmaceuticals that deliver radiation therapy directly and specifically to cancer cells. The company’s lead drug candidate, CycloSam(R), is a clinical-stage bone-seeking radiopharmaceutical designed to deliver targeted radiation safely and precisely to tumors in the bone. “QSAM is leading the charge to evaluate a new treatment for bone cancer and other related, underserved diseases. The company’s pioneering efforts are evident as the first patient has completed treatment in the company’s clinical trial designed to study the effect of its proprietary radiopharmaceutical technology: CycloSam(R),” a recent article reads.…

Continue Reading

ThursdayJul 28, 2022 11:58 am

BioMedNewsBreaks – Odyssey Health Inc. (ODYY) Dedicating Strategy Toward Acquisition, Creation of Lifesaving Medical Products

Odyssey Health (OTC: ODYY) continues to dedicate its operational strategy toward the acquisition and creation of lifesaving medical products. “Odyssey’s portfolio includes medical device candidates and pharmaceutical products in development that are responsive to conditions such as heart disease, foreign object-induced choking, neurodegenerative disorders, and brain concussion injuries. One drug product designed to treat mild traumatic injury within the first few minutes after an incident is advancing in a phase 1 clinical human trial following on preclinical lab animal tests that provided encouraging data, CEO Michael Redmond said in a June interview,” a recent article reads. “No U.S. Food and…

Continue Reading

ThursdayJul 28, 2022 10:58 am

BioMedNewsBreaks – Cybin Inc. (NEO: CYBN) (NYSE American: CYBN) CEO to Participate in Upcoming Canaccord Genuity Growth Conference

Cybin (NEO: CYBN) (NYSE American: CYBN), a biopharmaceutical company focused on progressing Psychedelics to Therapeutics(TM), will be presenting at the 42nd annual Canaccord Genuity Growth Conference; the four-day event is scheduled for Aug. 8–11, 2022, in Boston. During the conference, Cybin CEO Doug Drysdale will present a fireside chat. Drysdale’s presentation is slated for Thursday, Aug. 11, 2022, at 3:30 p.m. ET. Interested individuals are invited to watch a live webcast of the event or an archived version of the event, available on the company’s investor relations page following the live presentation. To view the live presentation, visit https://ibn.fm/ghBjR To view…

Continue Reading

WednesdayJul 27, 2022 10:44 am

BioMedNewsBreaks – Silo Pharma Inc. (SILO) Reports Positive Results from Study Evaluating Topically Administered Ketamine Formulation

Silo Pharma (OTCQB: SILO), a developmental stage biopharmaceutical company, has reported that its recent animal study evaluating topically administered ketamine reached a positive end point: using SILO’s selected formulation and partnered, patented delivery system, the study indicated reversal of allodynia and hyperalgesia. According to the announcements, the proprietary formulation reduced mechanical allodynia and hyperalgesia at both the pre-and post-dosing time points, with mechanical hyperalgesia reduced on day seven at the pre-dose time point. In short, the company reported, the results indicate that the dosing of ketamine using a patent-protected delivery system designed by Silo Pharma Zylo Therapeutics showed positive results…

Continue Reading